Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy

In locally advanced HNSCC treated with concurrent cisplatin and radiation, baseline leukocytosis predicts OS and PFS. In addition with HPV status, this independent biomarker could help identifying patients with high risk of tumor relapse.